Newron Pharmaceuticals S.p.A. (LON:0QOI)

Market Cap	130.71M
Revenue (ttm)	42.50M
Net Income (ttm)	13.10M
Shares Out	n/a
EPS (ttm)	0.64
PE Ratio	9.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14
Average Volume	366
Open	7.80
Previous Close	7.39
Day's Range	7.80 - 7.80
52-Week Range	5.34 - 10.80
Beta	0.94
RSI	52.76
Earnings Date	Sep 16, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QOI

Financial Performance

Financial numbers in EUR